Table 1.
Concentrations striatal (A) and hippocampal (B) Norepinephrine (NE), Dopamine (DA), 3,4-Dihydroxyphenylacetic acid (DOPAC), Serotonin (5-HT) and 5-Hydroxyindoleacetic acid (5-HIAA) in naïve control rats or those receiving unilateral medial forebrain bundle (MFB) 6-hydroxydopamine (n = 6–12/group) treated with Vehicle or the NE reuptake inhibitor desipramine (25 mg/kg, ip) 30 min prior to lesion. Values (as means ± S.E.M.) are expressed as picograms monoamine or metabolite per milligram wet weight of tissue. Differences between Side (Contralateral vs. Ipsilateral to 6-OHDA) and Lesion (Desipramine + 6-OHDA vs. 6-OHDA) were determined by 2-way ANOVA and planned comparison post-hocs. Differences between Desipramine-treated striatum contralateral to 6-OHDA vs. naïve control striata were examined with independent t-tests.
| A. ASTRIATUM
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Contralateral to 6-OHDA | NE | DA | DOPAC | 5-HT | 5-HIAA | |||||
| Desipramine-treated | 33±7 | 10185±639 | 2663±463 | 590±141 | 338±45 | |||||
| Vehicle-treated | 13±4* | 12605±551 | 4879±914 | 890±177 | 430±53 | |||||
| Ipsilateral to 6-OHDA | ||||||||||
| Desipramine-treated | 30±10 | 18±10+ | 31±11+ | 763 ±217 | 204±11 | |||||
| Vehicle-treated | 10±3* | 14±10+ | 138±47+ | 852±231 | 174±28+ | |||||
| Naïve Control | 36±3 | 14715±632# | 3160±307 | 508±59 | 557±55# | |||||
| B. HIPPOCAMPUS
|
||||||||||
| Contralateral to 6-OHDA | NE | DA | DOPAC | 5-HT | 5-HIAA | |||||
|
| ||||||||||
| Desipramine-treated | 733±307 | N/D | 182±67 | 812±91 | 300±85 | |||||
| Vehicle-treated | 88±23* | N/D | 120±36 | 860±319 | 163±68 | |||||
| Ipsilateral to 6-OHDA | ||||||||||
| Desipramine-treated | 703±212 | N/D | 50±19+ | 583±43 | 311±90 | |||||
| Vehicle-treated | 125±35* | N/D | 56±11+ | 330±184 | 248±92 | |||||
p<0.05 vs. Desipramine-treated.
p<0.05 vs. Contralateral side.
p<0.05 vs. Desipramine-treated Contralateral side.